Li R, Liu Z, Wei Z, Huang R, Pei Y, Yang J
J Cancer. 2025; 16(2):689-699.
PMID: 39744477
PMC: 11685702.
DOI: 10.7150/jca.103847.
Yamamoto M, Serizawa T, Sato Y, Higuchi Y, Kikuchi Y, Sato S
Clin Transl Radiat Oncol. 2024; 48:100820.
PMID: 39156739
PMC: 11328021.
DOI: 10.1016/j.ctro.2024.100820.
de Boisanger J, Brewer M, Fittall M, Tran A, Thomas K, Dreibe S
Curr Oncol. 2024; 31(6):2994-3005.
PMID: 38920712
PMC: 11202506.
DOI: 10.3390/curroncol31060228.
Mangesius J, Seppi T, Arnold C, Mangesius S, Kerschbaumer J, Demetz M
Curr Oncol. 2024; 31(4):1739-1751.
PMID: 38668035
PMC: 11049204.
DOI: 10.3390/curroncol31040132.
Benkhaled S, Schiappacasse L, Awde A, Kinj R
Cancers (Basel). 2024; 16(6).
PMID: 38539428
PMC: 10968598.
DOI: 10.3390/cancers16061093.
The association between graded prognostic assessment and the prognosis of brain metastases after whole brain radiotherapy: a meta-analysis.
Geng X, Kou C, Wang J
Front Oncol. 2024; 13:1322262.
PMID: 38264750
PMC: 10803601.
DOI: 10.3389/fonc.2023.1322262.
Navigating Post-Operative Outcomes: A Comprehensive Reframing of an Original Graded Prognostic Assessment in Patients with Brain Metastases.
Goldberg M, Mondragon-Soto M, Dieringer L, Altawalbeh G, Poser P, Baumgart L
Cancers (Basel). 2024; 16(2).
PMID: 38254781
PMC: 10813622.
DOI: 10.3390/cancers16020291.
Validation of the ALK-Brain Prognostic Index for patients with ALK-rearranged lung cancer and brain metastases.
Zerdes I, Kamali C, Koulouris A, Elsayed M, Schnorbach J, Christopoulos P
ESMO Open. 2023; 8(6):102069.
PMID: 37988952
PMC: 10774967.
DOI: 10.1016/j.esmoop.2023.102069.
Pretreatment lymphocyte-to-monocyte ratio as a prognostic factor and influence on dose-effect in fractionated stereotactic radiotherapy for oligometastatic brain metastases in non-small cell lung cancer patients.
Chen T, Tang M, Zhou Y, Wang Z, Li S, Wang H
Front Oncol. 2023; 13:1216852.
PMID: 37456254
PMC: 10348423.
DOI: 10.3389/fonc.2023.1216852.
Stereotactic Radiosurgery as Treatment for Brain Metastases: An Update.
Pena-Pino I, Chen C
Asian J Neurosurg. 2023; 18(2):246-257.
PMID: 37397044
PMC: 10310446.
DOI: 10.1055/s-0043-1769754.
Efficacy and safety of combined immunotherapy and stereotactic radiosurgery in NSCLCBM patients and a novel prognostic nomogram: A real-world study.
Bashir S, Wen L, Zhang P, Ye M, Li Y, Hong W
Front Oncol. 2023; 13:1068592.
PMID: 37124533
PMC: 10141675.
DOI: 10.3389/fonc.2023.1068592.
The First Survival Score for Patients Treated with Whole-Brain Radiotherapy Plus Simultaneous Integrated Boost for Brain Metastases.
Rades D, Johannwerner L, Werner E, Cremers F, Yu N
Biology (Basel). 2023; 12(4).
PMID: 37106785
PMC: 10135994.
DOI: 10.3390/biology12040585.
New prognostic system specific for epidermal growth factor receptor-mutated lung cancer brain metastasis.
Zhu L, Fan X, Sun L, Ni T, Li Y, Wu C
Front Oncol. 2023; 13:1093084.
PMID: 37020869
PMC: 10067922.
DOI: 10.3389/fonc.2023.1093084.
Prognostic impact of extracranial disease control in HER2+ breast cancer-related brain metastases.
Bottosso M, Griguolo G, Sinoquet L, Guarascio M, Aldegheri V, Miglietta F
Br J Cancer. 2023; 128(7):1286-1293.
PMID: 36717671
PMC: 10049979.
DOI: 10.1038/s41416-023-02153-w.
Added survival benefit of whole brain radiotherapy in brain metastatic non-small cell lung cancer: Development and external validation of an individual prediction model.
Trikhirhisthit K, Setakornnukul J, Thephamongkhol K
Front Oncol. 2023; 12:911835.
PMID: 36591469
PMC: 9796174.
DOI: 10.3389/fonc.2022.911835.
A novel quantitative prognostic model for initially diagnosed non-small cell lung cancer with brain metastases.
Li X, Gu W, Liu Y, Wen X, Tian L, Yan S
Cancer Cell Int. 2022; 22(1):251.
PMID: 35948974
PMC: 9367158.
DOI: 10.1186/s12935-022-02671-2.
Retrospective study of hypofractionated stereotactic radiotherapy combined with whole brain radiotherapy for patients with brain metastases.
Xie X, Peng H, Zhang X, Pan Y, Zhang Z, Cao P
Radiat Oncol. 2022; 17(1):132.
PMID: 35883147
PMC: 9327356.
DOI: 10.1186/s13014-022-02096-1.
Predictors of Lung Adenocarcinoma With Leptomeningeal Metastases: A 2022 Targeted-Therapy-Assisted molGPA Model.
Zhang M, Tong J, Ma W, Luo C, Liu H, Jiang Y
Front Oncol. 2022; 12:903851.
PMID: 35795063
PMC: 9252592.
DOI: 10.3389/fonc.2022.903851.
The Usefulness of Prognostic Tools in Breast Cancer Patients with Brain Metastases.
Kufel-Grabowska J, Niwinska A, Radecka B, Ali S, Mandat T, Duchnowska R
Cancers (Basel). 2022; 14(5).
PMID: 35267407
PMC: 8909185.
DOI: 10.3390/cancers14051099.
Stereotactic radiosurgery results for brain metastasis patients with renal cancer: A validity study of Renal Graded Prognostic Assessment and proposal of a new grading index (JLGK2101 Study).
Okuno-Ito R, Yamamoto M, Sato Y, Serizawa T, Kawagishi J, Shuto T
Clin Transl Radiat Oncol. 2022; 32:69-75.
PMID: 34984241
PMC: 8693359.
DOI: 10.1016/j.ctro.2021.11.002.